Business Wire

Aviatrix Automates Cloud Networking Within AWS Control Tower to Ensure Organizations Have a ‘Well-Architected’ Network Topology

25.8.2020 16:00:00 EEST | Business Wire | Press release

Share

Aviatrix, the cloud network platform, today announced new capabilities to automate enterprise network infrastructure deployment and operations for organizations using the account factory feature of AWS Control Tower. Available now in AWS Marketplace, the integrated Aviatrix software serves as the network factory for newly provisioned accounts on Amazon Web Services (AWS). The solution helps enterprise organizations meet cloud governance and regulatory initiatives for their multi-account, multi-region cloud networks.

Join experts from Aviatrix and AWS on Thursday, August 27th as they host a live, online session to highlight the new AWS Control Tower and Aviatrix network factory capabilities. For more information or to register, go here.

“With AWS Control Tower, it only takes a few clicks for enterprise organizations to provision new AWS accounts that conform to company-wide policies,” said Chris Grusz, Director, AWS Marketplace, Amazon Web Services, Inc. “The Aviatrix cloud networking solution uniquely offers a network factory for AWS Control Tower. With AWS Control Tower account factory ensuring account control governance, customers will benefit from Aviatrix’s new capabilities that make certain the network infrastructure supporting those accounts is secure and correctly deployed every time.”

AWS Control Tower provides the easiest way to set up and govern new, secure, multi-account AWS environments. Additionally, AWS Service Catalog enables organizations to create and manage catalogs of approved IT services for use on AWS. The Aviatrix cloud network platform provides the prescriptive transit network architecture and operational visibility that meets enterprise cloud networking and security requirements. The Aviatrix software is able to create Amazon Virtual Private Clouds (Amazon VPCs), automate route table updates and ensure network correctness by preventing overlapping CIDRs, while also enforcing IT security controls through policy-based network segmentation. The integrated solution enables self-service delivery of new account infrastructure, provides detailed operational visibility, and helps ensure IT networking and security teams achieve compliance through a simple, automated workflow.

“In the journey to leverage cloud-based infrastructure we are always on the lookout for ways to streamline the automated delivery of services, in the simplest, most secure manner,” said Justin Donohoo, CTO at Observian. “The Aviatrix cloud network platform delivers the network architecture, advanced network, security controls, and operational visibility enterprises need. I view the integration of Aviatrix with AWS Control Tower as a natural evolution to streamline the delivery of new AWS infrastructure. Leveraging Aviatrix as the network factory and the AWS Control Tower account factory ensures that both AWS accounts and enterprise network infrastructure are deployed correctly and in compliance with corporate policies and industry regulations.”

Provisioning cloud network services is often easier than operationalizing them. AWS Control Tower customers who need to be in full control of their cloud network environment can also use the Aviatrix software to access the network intelligence they need – all in one place – instead of logging into multiple screens, services and management consoles to stitch together the network visibility they require. Aviatrix CoPilot – an available component of the integrated solution for AWS Control Tower - provides a global view of the cloud environment by leveraging intelligence and analytics from the Aviatrix cloud network platform combined with telemetry and network information gathered using native AWS APIs. CoPilot’s rich, intuitive visualizations provide actionable insights to practitioners by using dynamic multi-cloud topology maps, FlowIQ intelligent traffic flow analytics, global traffic heat maps, time series trend charts and a complete cloud network monitoring dashboard.

“AWS Control Tower is a leap forward for enterprise IT teams who are tasked with maintaining control over their networks, without becoming a bottleneck to their organization’s cloud agility and speed,” said Nauman Mustafa, VP of Solution Engineering at Aviatrix. “Regulatory compliance and corporate governance must be automated and adopted for the cloud era. The combination of AWS Control Tower and Aviatrix cloud network platform delivers the simplicity and automation along with enterprise visibility and control.”

Availability and How to Get Started

Aviatrix cloud network platform for AWS Control Tower is available immediately in AWS Marketplace. More technical information on the integrated solution - including how to get started - is available here. For a live demo or further information, please email info@aviatrix.com

About Aviatrix

Aviatrix cloud network platform delivers advanced networking, security and operational visibility required by enterprises with the simplicity and automation of cloud. More than 400 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at Aviatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aviatrix
Frank Cabri
frank@aviatrix.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye